MR antagonist, spironolactone, decreased stress-induced amygdala activity and improved cognitive function in MDD patients [242], but TRD patients were unresponsive to treatment [243] indicating that MR dysfunction could contribute to TRD. This evidence concerns the gene NR3C2 and major depressive disorder.